Virax Biolabs Group Ltd. Class A(VRAX)
$0.45-0.00 (-0.67%)
VRAX
Virax Biolabs Group Ltd. Class A financials statements
$0.45
At close:-0.00 (-0.67%)
Virax Biolabs Group Ltd. Class A (VRAX) Ratios
170 Followers
Virax Biolabs Group Ltd. Class A Ratios
VRAX's free cash flow for Q4 2026 was $-4.88M. For the 2026 fiscal year, VRAX's free cash flow was decreased by $-255.83K and operating cash flow was $-4.62M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Sep 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 9.97 | 7.27 | 25.94 | 10.61 | 0.04 |
| Quick Ratio | 9.90 | 7.13 | 25.58 | 10.58 | 0.02 |
| Cash Ratio | 9.40 | 6.28 | 21.26 | 10.30 | 0.02 |
| Solvency Ratio | -4.63 | -5.93 | -19.21 | -6.01 | 0.02 |
| Operating Cash Flow Ratio | -6.75 | -6.78 | -37.00 | -4.60 | -0.65 |
| Short-Term Operating Cash Flow Coverage | -162.30 | -140.56 | 0.00 | -28.58 | 0.00 |
| Net Current Asset Value | $ 5.84M | $ 3.93M | $ 4.04M | $ 8.73M | $ -1.20M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.06 | 0.04 | 0.01 | 0.08 |
| Debt-to-Equity Ratio | 0.05 | 0.07 | 0.04 | 0.02 | -0.00 |
| Debt-to-Capital Ratio | 0.05 | 0.06 | 0.04 | 0.02 | -0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.10 | 1.13 | 1.02 | 1.08 | -0.05 |
| Debt Service Coverage Ratio | -50.21 | -62.50 | -245.89 | -33.65 | -0.05 |
| Interest Coverage Ratio | -103.60 | -105.93 | -241.70 | -370.62 | -112.30 |
| Debt to Market Cap | 0.01 | 0.01 | 0.00 | 0.02 | 0.00 |
| Interest Debt Per Share | 1.20 | 3.51 | 0.13 | 0.15 | 0.02 |
| Net Debt to EBITDA | 1.11 | 0.66 | 0.51 | 1.69 | 24.00 |
| Profitability Margins | |||||
| Gross Profit Margin | 61.90% | -838.21% | 32.34% | -15.94% | 0.00% |
| EBIT Margin | -47256.31% | -97073.35% | -4291.19% | -63570.74% | 0.00% |
| EBITDA Margin | -43722.40% | -91649.46% | -4225.28% | -63570.74% | 0.00% |
| Operating Profit Margin | -51515.17% | -97344.76% | -4153.25% | -66963.67% | 0.00% |
| Pretax Profit Margin | -47753.55% | -97992.31% | -4308.38% | -63751.47% | 0.00% |
| Net Profit Margin | -40439.10% | -95739.17% | -4304.81% | -63748.32% | 0.00% |
| Continuous Operations Profit Margin | -40507.00% | -95833.71% | -4308.38% | -63751.47% | 0.00% |
| Net Income Per EBT | 84.68% | 97.70% | 99.92% | 100.00% | 97.65% |
| EBT Per EBIT | 92.70% | 100.67% | 103.74% | 95.20% | 100.93% |
| Return on Assets (ROA) | -60.35% | -94.31% | -122.79% | -55.62% | -3508.45% |
| Return on Equity (ROE) | -66.30% | -106.41% | -125.47% | -59.80% | 175.34% |
| Return on Capital Employed (ROCE) | -83.77% | -107.11% | -122.23% | -64.38% | 144.87% |
| Return on Invested Capital (ROIC) | -70.05% | -103.22% | -121.13% | -63.34% | 144.87% |
| Return on Tangible Assets | -60.35% | -94.90% | -123.91% | -56.65% | -3508.45% |
| Earnings Yield | -229.74% | -171.67% | -456.60% | -73.83% | -0.83% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.21 | 0.72 | 0.00 | 0.00 |
| Payables Turnover | 0.09 | 1.06 | 2.32 | 0.06 | 0.00 |
| Inventory Turnover | 0.10 | 0.63 | 1.75 | 0.41 | 0.00 |
| Fixed Asset Turnover | 0.01 | 0.00 | 0.14 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
| Cash Conversion Cycle | -287.19 | 2004.38 | 559.21 | -4994.13 | 0.00 |
| Days of Sales Outstanding | 0.00 | 1767.29 | 508.33 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 3704.91 | 581.78 | 208.26 | 886.02 | 0.00 |
| Days of Payables Outstanding | 3992.10 | 344.69 | 157.38 | 5880.16 | 0.00 |
| Operating Cycle | 3704.91 | 2349.07 | 716.59 | 886.02 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -11.62 | -36.84 | -3.11 | -3.93 | -0.71 |
| Free Cash Flow Per Share | -12.27 | -41.71 | -3.69 | -4.10 | -0.71 |
| Dividend Paid and CapEx Coverage Ratio | -18.07 | -7.56 | -5.36 | -23.43 | 0.00 |
| Capital Expenditure Coverage Ratio | -18.07 | -7.56 | -5.36 | -23.43 | 0.00 |
| Operating Cash Flow Coverage Ratio | -11.15 | -12.10 | -27.85 | -28.58 | -215.29 |
| Operating Cash Flow to Sales Ratio | -372.04 | -720.83 | -39.94 | -488.23 | 0.00 |
| Free Cash Flow Yield | -223.06% | -146.36% | -502.57% | -58.96% | -0.39% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.44 | -0.58 | -0.22 | -1.35 | -121.14 |
| Price-to-Sales (P/S) Ratio | 176.02 | 557.68 | 9.43 | 863.45 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.29 | 0.62 | 0.27 | 0.81 | -212.41 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.45 | -0.68 | -0.20 | -1.70 | -255.86 |
| Price-to-Operating Cash Flow Ratio | -0.47 | -0.77 | -0.24 | -1.77 | -255.86 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | 0.01 | 0.01 | -0.01 | -0.74 |
| Enterprise Value Multiple | 0.71 | 0.06 | 0.29 | 0.33 | -275987.25 |
| Enterprise Value | -3.84M | -321.25K | -1.89M | -1.81M | 206.99M |
| EV to EBITDA | 0.71 | 0.06 | 0.29 | 0.33 | -275987.25 |
| EV to Sales | -308.93 | -50.74 | -12.08 | -211.93 | 0.00 |
| EV to Free Cash Flow | 0.79 | 0.06 | 0.26 | 0.42 | -255.84 |
| EV to Operating Cash Flow | 0.83 | 0.07 | 0.30 | 0.43 | -255.84 |
| Tangible Book Value Per Share | 18.45 | 43.77 | 2.54 | 8.21 | -1.05 |
| Shareholders’ Equity Per Share | 19.06 | 45.98 | 2.67 | 8.59 | -0.86 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.15 | 0.02 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.03 | 0.05 | 0.08 | 0.01 | 0.00 |
| Net Income Per Share | -12.64 | -48.93 | -3.36 | -5.13 | -1.50 |
| Tax Burden | 0.85 | 0.98 | 1.00 | 1.00 | 0.98 |
| Interest Burden | 1.01 | 1.01 | 1.00 | 1.00 | 1.01 |
| Research & Development to Revenue | 300.92 | 281.12 | 9.99 | 46.39 | 0.00 |
| SG&A to Revenue | 214.85 | 683.94 | 29.37 | 619.98 | 0.00 |
| Stock-Based Compensation to Revenue | 10.50 | 57.70 | 6.47 | 202.62 | 0.00 |
| Income Quality | 0.92 | 0.75 | 0.93 | 0.77 | 0.47 |
Currency in USD

